We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, pr... Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab. Show more
Ask ADVFN Intelligence (AI)
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.8898 | 17.7604790419 | 5.01 | 5.95 | 4.8803 | 11398 | 5.15493166 | CS |
| 4 | 0.8998 | 17.996 | 5 | 5.95 | 4.5 | 9846 | 4.97230205 | CS |
| 12 | -3.8502 | -39.4892307692 | 9.75 | 9.89 | 4.44 | 64388 | 7.68831816 | CS |
| 26 | -10.7677 | -64.6029698515 | 16.6675 | 17.75 | 4.44 | 79277 | 10.44468411 | CS |
| 52 | -18.8502 | -76.1624242424 | 24.75 | 24.75 | 4.44 | 86292 | 12.68315514 | CS |
| 156 | -18.8502 | -76.1624242424 | 24.75 | 24.75 | 4.44 | 86292 | 12.68315514 | CS |
| 260 | -18.8502 | -76.1624242424 | 24.75 | 24.75 | 4.44 | 86292 | 12.68315514 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
